← Back to China
CN

BeiGene

6160 · HKEX · Health Care · Oncology Biopharmaceuticals · US listing: BGNE

BeiGene is number 39 by indicative market capitalization among the 50 listed companies tracked here for China (data year 2024).

About the company

BeiGene is a global oncology biotechnology company founded in Beijing, focused on developing and commercialising targeted therapies and cancer immunotherapies. The company has listings on HKEX, NASDAQ (BGNE), and the SSE STAR Market. Its principal research and commercial operations are in China and the United States.

ExchangeHKEX
Ticker6160
SectorHealth Care · Oncology Biopharmaceuticals
US listingBGNE
Indicative market cap USD$18.00B
WebsiteVisit website

Live quote

Loading live price…

Where to buy

Trades in the US as BGNE, available through most US brokerage accounts.

On its home market (HKEX), it is accessible through global brokers that offer that exchange:

Availability information only. Not a recommendation or an offer to buy. Confirm eligibility, fees and current availability with your broker.

Other ways to get exposure

Single-country ETFs covering China (a fund may or may not hold this company; check its holdings):

Other companies in China

Company data and any live price are indicative, may be delayed or inaccurate, and are for research only. Not investment advice. Verify with the exchange, the company's filings and your broker. Report an error

Theme